Join Oakwood Labs for a complimentary webinar on August 24^th, 2021 at 11 a.m. EST. This webinar will discuss a corporate overview and Oakwood’s approach to development of extended-release and long-acting injectables.

Oakwood’s capabilities include the following:

• Pre-formulation development activities
• Feasibility studies
• Scale-up of formulation
• Manufacturing toxicology batches
• ICH compliant stability testing
• Clinical trial manufacturing (Phase I, II, III)
• Commercial aseptic GMP manufacturing

Reach Out to Oakwood Labs Today About Extended-Release Injectables

Contact us today to learn more about the extended-release solutions we can provide for your company. We look forward to hearing from you.

• Author
• Recent Posts

Mark Ilhan

Mark Ilhan joined Oakwood Labs in 2013. Over the last 7 years he has worked to establish and maintain relationships with a variety of global pharmaceutical clients. Primary activities include representing Oakwood at global conferences with the scientific team, creating drug development proposals, and strategic marketing. His expertise is in Business Development and Project Management. He received a Bachelor’s degree in Management and Finance from Case Western University, and an MBA from Cleveland State University.

Latest posts by Mark Ilhan (see all)

• How Long-Acting Injectables Are Utilized in Pulmonary Arterial Hypertension Pharmaceutical Development - March 5, 2025
• The Role of Long-Acting Injectables in Acromegaly and Carcinoid Tumor Pharmaceutical Treatment for Endocrinology - February 5, 2025
• Opioid Use Disorder: Developing Long-Acting Injectables for Treatment - November 5, 2024